CD4+ T Cell Generation from Pluripotent Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining CD4+ T effector (Teff) and regulatory (Treg) cells are invasive, time-consuming, and yield only small numbers of polyclonal cells, which can introduce variability in immunosuppressive responses, and simply increasing Treg numbers may not be sufficient to control diseases.
Innovation Solution
A method involving the culture of CD4+CD8+ immature T cells with phorbol 12-myristate 13-acetate (PMA) and ionomycin to enrich for CD4 single positive T cells, followed by further differentiation in media with IL-2, anti-CD2, anti-CD3, and anti-CD28 antibodies, and optionally TGF-β and all-trans retinoic acid, to obtain enriched populations of CD4+ Teff and Treg cells, which can be genetically engineered for enhanced functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If CD4+ Teff and Treg cells are obtained from adult or adolescent primary blood and tissue sources, then the cells can be used for cell therapies, but the isolation process is invasive, time-consuming, and yields only small numbers of polyclonal cells
Solution Approach 1:
The patent uses pluripotent stem cells as a starting material that can be expanded and differentiated in advance to produce large numbers of CD4+ Teff and Treg cells, eliminating the need for time-consuming isolation from primary blood and tissue sources. This preliminary preparation of stem cell cultures enables on-demand generation of therapeutic cell populations.
Solution Approach 2:
The patent creates copies of desired T cell populations by differentiating pluripotent stem cells into CD4+ Teff and Treg cells through controlled culture conditions. This copying process from stem cells allows generation of large numbers of cells without the limitations of primary source isolation.
2Reliability
If polyclonal CD4+ Teff and Treg cells are obtained from primary sources, then the cells represent natural diversity, but they introduce variability in immunosuppressive response
Solution Approach 1:
The patent applies local quality by using genetic engineering to introduce specific transgenes into individual T cells, creating cells with defined, uniform characteristics. This allows each cell to have precisely controlled immunosuppressive properties while maintaining the ability to target specific antigens, thereby achieving consistency without sacrificing functionality.
3Reliability
If simply increasing Treg numbers is used to control disease, then the approach is straightforward, but it may not be sufficient to achieve disease control
Solution Approach 1:
The patent changes key parameters of Treg cells through genetic engineering, introducing transgenes that enhance immunosuppressive function, alter cytokine profiles, or improve persistence. These parameter changes transform standard Tregs into therapeutically optimized cells with superior disease control capability beyond what is achieved by simple number increases.
Data Source
AI summary
Provided herein are improved methods and compositions for generating CD4-positive effector T cells and regulatory T cells and methods of use thereof.